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Abstract
Background—Medication adherence and perceived social support are independent predictors of
mortality in patients with heart failure (HF). However, the predictive power of the combination of
medication adherence and perceived social support for hospitalization and death has not been
investigated in patients with HF.
Objective—To explore the combined influence of medication adherence and perceived social
support for prediction of cardiac event-free survival in patients with HF.
Method and Results—A total of 218 HF patients monitored medication adherence for 1-3
months and completed the Multidimensional Perceived Social Support Scale (MPSSS) at baseline.
Medication adherence was measured using a valid and objective measure, Medication Event
Monitoring System (MEMS). Patients were followed for up to 3 1/2 years to collect data about
cardiac event-free survival (i.e., cardiac emergency department visits, hospitalizations, and death).
To test the association of the combination of medication adherence and perceived social support
with outcomes, first, the interaction term of medication adherence and perceived social support
was entered in a Cox regression to predict outcomes. Second, patients were grouped using an
evidence-based cut-point of 88% for medication adherence from the MEMS data and a median
score 71 of the MPSSS. Kaplan-Meier and Cox proportional hazards models were used to
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compare cardiac event-free survival among groups. Medication adherence and perceived social
support were independent predictors of cardiac event-free survival (p = .006 and .021,
respectively). Patients with medication nonadherence and lower PSS had a 3.5 times higher risk of
cardiac events than those who were adherent and had higher PSS.
Conclusion—Medication adherence mediated the relationship between perceived social support
and cardiac event-free survival in this sample. Moreover, medication adherence and social support
independently, and in combination, predicted cardiac event-free survival in patients with HF.
Interventions to improve clinical outcomes should address both medication adherence and social
support.
INTRODUCTION
Heart failure (HF) is a chronic condition that requires patients to consistently adhere to their
prescribed medications to prevent exacerbations that lead to emergency department (ED)
visits, hospital admissions, or death (Chin & Goldman, 1997b; Chui et al., 2003; Happ,
Naylor, & Roe-Prior, 1997; Joshi, Mohanan, Sengupta, & Salkar, 1999; Li, Morrow-Howell,
& Proctor, 2004; Miura et al., 2001). Social support has been widely studied in many
conditions and is an important factor that contributes to physical and mental health
(DiMatteo, 2004). There are two main types of social support: structural (e.g., marital status,
living arrangement) and functional (e.g., practical/instrumental, emotional, family cohesion)
social support (DiMatteo, 2004). Patients with HF need effective social support to help them
adhere to their prescribed medications, keep their health care provider appointments, refill
prescriptions, and in some instances, administer the medications (DiMatteo, 2004; Riegel, et
al., 2009; Sayers, Riegel, Pawlowski, Coyne, & Samaha, 2008; Wu, et al., 2008). Without
adequate social support, patients with HF are likely to fail to adhere to their medication
prescriptions (DiMatteo, 2004; Riegel, et al., 2009; Sayers, et al., 2008; Wu, Moser, Lennie,
et al., 2008).
Hospitalization and mortality rates are higher in HF patients with lower social support
compared to patients with higher social support (Burg, et al., 2005; Chin & Goldman,
1997a; Happ, et al., 1997; Krumholz et al., 1998; Lofvenmark, Mattiasson, Billing, & Edner,
2009; Luttik, Jaarsma, Moser, Sanderman, & van Veldhuisen, 2005; Schwarz & Elman,
2003; Tsuchihashi-Makaya, Kato, Chishaki, Takeshita, & Tsutsui, 2009; Vinson, Rich,
Sperry, Shah, & McNamara, 1990; Wright, et al., 2003). Luttik et al. (2005) reviewed
studies published from 1993 to 2003 of the relationship between social support and
hospitalization and death and found that lower social support was related to more hospital
readmissions and deaths. In a prospective study, Tsuchihashi-Makaya et al. (2009) followed
139 patients with HF for 12 months and found that patients with lower social support had a
significantly higher rate of HF-related readmissions than those with higher social support. In
prior studies, medication adherence independently predicted emergency department visits,
hospitalizations, and death in patients with HF (Ambardekar, et al., 2009; Annema, Luttik,
& Jaarsma, 2009; Chui, et al., 2003; Cole, Norman, Weatherby, & Walker, 2006; Esposito,
Bagchi, Verdier, Bencio, & Kim, 2009; Granger et al., 2005; Li, et al., 2004; Miura, et al.,
2001; Murray et al., 2009; Murray et al., 2007; Sun, Ye, Lee, Dupclay, & Plauschinat, 2008;
Wu, Moser, Chung, & Lennie, 2008). However, the power of the combination of medication
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adherence and perceived social support for prediction of cardiac event-free survival has not
been previously investigated in patients with HF. Accordingly; the purpose of this study was
to explore the predictive power of the combination of medication adherence and perceived
social support for cardiac event-free survival in patients with HF.
METHODS
Study Design
This was secondary data analysis using data from two prospective, longitudinal studies in
which medication adherence was measured using the MEMS. Patients with HF were
followed to collect data about cardiac events (ED visits, hospitalizations, and deaths) (Wu,
Corley, Lennie, & Moser, 2012; Wu, et al., 2008). Both studies used identical inclusion and
exclusion criteria; all patients were recruited from an academic medical center in one
Southern state. In the current study, we explored the association of the combination of
medication adherence and perceived social support with cardiac even-free survival in
patients with HF.
Procedure
Both studies received approval from the appropriate Institutional Review Boards. A trained
research nurse confirmed patient eligibility, explained study requirements to eligible
patients, and all patients provided written, informed consent.
Patient sociodemographic and clinical characteristics were collected by interview and
medical record review at baseline. After completion of the baseline assessment, detailed
written and verbal instructions about the use of the MEMS bottle were then given to
patients. Patients were instructed to take the specified medicine from the MEMS bottle and
to close the cap after each use. A MEMS diary was given to patients to record unscheduled
MEMS cap openings (defined as all cap openings unrelated to taking medications, such as
refill without taking medications).
Patients returned the MEMS bottle after one or three months of daily use of the MEMS
device. The MEMS data were downloaded to a personal computer and transferred into a
database for analysis. Unscheduled cap openings were excluded from analysis based on the
MEMS diary recorded by patients. Outcome data about ED visits, hospitalizations and death
were collected for up to 3.5 years.
Samples and Setting
Patients enrolled in this study were recruited from outpatient cardiology clinics and inpatient
cardiology units. We recruited patients who had a confirmed diagnosis of chronic HF and
were prescribed stable doses of HF medications. Patients who had a myocardial infarction or
stroke within 3 months, obvious cognitive impairment, were discharged to a skilled nursing
facility, or were diagnosed with a co-existing terminal illness were excluded.
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Medication adherence: Medication adherence was measured daily for 1-3 months (3
months for the first study and 1 month for the second study) using a microelectronic
medication monitoring device (MEMS, AARDEX®-USA, Union City, CA). The MEMS
recorded the date and time of each cap opening. MEMS data were collected for one
prescribed HF medication with priority given to medications taken twice a day. The
medication chosen for monitoring using the MEMS was selected in the following order:
beta-adrenergic antagonist agent, angiotensin-converting-enzyme inhibitor (ACEI),
angiotensin receptor blocker (ARB), aldosterone antagonist, digoxin, or a diuretic.
Medication adherence from the MEMS was defined as the percentage of days the correct
number of doses was taken during the monitoring period (Chung et al., 2008). Patients who
took the correct number of doses on at least 88% of days were categorized as adherent; all
others were categorized as nonadherent. This cutpoint was chosen based on a recent study
demonstrating that adherence at or above 88% predicted better event-free survival (Wu, et
al., 2009).
Perceived social support: Perceived social support (PSS), subjective self-reported
perceived social support from family, friends, or others, was measured using the
Multidimensional Perceived Social Support Scale (MPSSS) (Canty-Mitchell & Zimet, 2000;
Picardi et al., 2005). The MPSSS consists of 12 items rated using a 7-point Likert scale from
1 (very strongly disagree) to 7 (very strongly agree). The instrument is scored by adding the
item ratings. The total score can range from 12 to 84, with higher scores reflecting higher
levels of perceived social support from family, friends, or significant others. The MPSSS is
a reliable and valid instrument (Canty-Mitchell & Zimet, 2000; Picardi, et al., 2005).
Internal consistency reliability of the MPSSS for this study was demonstrated by a
Cronbach's alpha of .85.
Outcome variable—The outcome variable was the composite end-point of time to the
first occurrence of one of the following events: cardiac ED visits, cardiac hospitalizations,
and cardiac mortality (i.e., cardiac event-free survival). Patients were followed for up to 3
1/2 years to collect data about cardiac events by patient/family interview, and confirmed by
medical records and/or death certificates. The date and reasons for ED visits, hospitalization
and death were captured by a research assistant.
Variables of interest
Demographics: Age, gender, ethnicity, and whether the patient lived alone or not were
collected as demographic factors by patient interview and medical record review.
Clinical variables: Left ventricular ejection fraction (LVEF), New York Heart Association
(NYHA) functional class, functional status, body mass index (BMI), history of hypertension
and diabetes, presence of depressive symptoms, angiotensin-converting enzyme inhibitor
(ACEI) use, and beta-antagonist use were collected as clinical variables to characterize/
compare patients by groups. NYHA class was assessed by careful patient interview and was
based on how patients were able to perform their daily activities related to HF symptoms
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(Mills & Haught, 1996). Functional status was measured using the Duke Activity Status
Index (DASI). The DASI consists of 12 items. The total score can range from 0 to 58.2, with
higher scores indicating better functional status. The DASI is a reliable and valid
questionnaire (Parissis, et al., 2009). In this study, Cronbach's alpha was .83.
Depressive symptoms are an important and well-known factor associated with increased
morbidity and mortality (Carney, Freedland, Miller, & Jaffe, 2002; Macchia, et al., 2008;
Okonkwo, Sui, & Ahmed, 2007). In this study, depressive symptoms were included as a
potential confounder in the Cox regression modeling and were measured using the Patient
Health Questionnaire-9 (PHQ-9) (Ackermann, et al., 2005; Kroenke, Spitzer, & Williams,
2001). The PHQ-9 consists of nine items on a scale rated from 0 (not at all) to 3 (nearly
every day). Total scores of the PHQ-9 can range from 0 to 27; higher scores indicate worse
depressive symptoms. The PHQ is a reliable (Kroenke, et al., 2001) and valid (Ackermann,
et al., 2005; Kroenke, et al., 2001) scale that has been used to measure depression level in
patients with HF (Ackermann, et al., 2005). In this study, Cronbach's alpha was .83.
Patient LVEF, history of hypertension and diabetes, ACEI use and beta-antagonist use were
abstracted from the medical record or collected by patient interview. BMI was calculated as
weight (kg)/height (m2).
Data Management and Analysis
All data analyses were performed using SPSS (Chicago, IL), version 18.0; a p value of .05
indicated significance. Patient characteristics were summarized using means and standard
deviations or frequency distributions. Differences in demographic and clinical variables
between the two studies were assessed with independent t-tests or chi-square tests of
association based on the level of measurement.
We conducted the analyses with medication adherence and perceived social support as
continuous variables. First, we tested whether medication adherence was a mediator between
perceived social support and cardiac events following the steps outlined by Baron et al.
(Baron & Kenny, 1986; Bennett, 2000; MacKinnon, Lockwood, Hoffman, West, & Sheets,
2002; MacKinnon, MacKinnon, & Dwyer, 1993). Second, we entered the interaction term of
medication adherence and perceived social support into a Cox proportional hazards
regression model to predict cardiac event-free survival from the combination of medication
adherence and perceived social support in patients with HF.
Following these analyses, an evidence-based cutpoint of 88% medication adherence for the
monitored time using the MEMS (Wu, et al., 2009) was used to categorize patients into
adherent and nonadherent groups. Patients were also categorized as higher or lower social
support groups based on the median score of the MPSSS (71); the median score was used
because there is no established cutpoint for this scale. Based on these categories, patients
were divided into 4 groups: (1) medication adherent with higher PSS; (2) medication
adherent with lower PSS; (3) medication nonadherent with higher PSS; and (4) medication
nonadherent with lower PSS. Log-rank tests were used to compare the time to cardiac event-
free survival between patients in medication adherent and nonadherent groups, in lower and
higher PSS patients, and among the four groups defined by combinations of adherence and
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PSS. Kaplan-Meier plots and log-rank tests were used to depict and test for group
differences in cardiac event-free survival. Cox proportional hazards regression modeling
was used to assess the time to cardiac event-free survival among these four groups with and
without adjusting for the following potential confounding variables: age, gender, ethnicity,
living status, NYHA functional class, and depressive symptoms. To account for potential




A total of 218 patients with HF and complete MEMS data were included in the analysis. The
mean age and standard deviation of the patients was 60 ± 12 years; about two thirds of
patients were male and more than half had advanced HF (NYHA class III or IV) with an
average LVEF of 36 ± 14%. The majority of the patients were Caucasians (85%) who lived
with another person (74%). In Table 1, the baseline characteristics of patients recruited in
study 1 (n = 136) and study 2 (n = 82) were compared. The percentage of patients who were
in NYHA Class III/IV HF was 60% for the study 1 and 50% for the study 2 (p = .04) and
there were fewer minority patients in study 1 (10% vs. 22%, p = .03). No other demographic
and clinical characteristic differed between the two study groups.
When we compared the characteristics of the 4 patient groups stratified by medication
adherence and perceived social support, there were significant differences in living status
and depressive symptoms among groups (Table 2). Patients who reported higher perceived
social support tended to live with others compared with those who had lower perceived
social support (p = .001). Patients who were medication adherent and had higher perceived
social support also reported fewer depressive symptoms compared with those in the other
three groups. No other demographic and clinical characteristic differed among the four study
groups.
Medication Adherence
Comparisons of medication adherent vs. non-adherent and high vs. low PSS groups are
presented in Table 3. The mean of medication adherence (percentage of days the correct
number of doses taken) was 83 ± 21%. Of the total sample, 129 (59%) were classified as
adherent to prescribed HF medication, while 90 patients (41%) were nonadherent (cutpoint
88%). Patients with medication nonadherence reported more depressive symptoms (p = .01)
than those who were adherent.
Perceived Social Support (PSS)
The mean score of the MPSSS was 66.9 ± 19.5 and the median was 71, indicating
moderately high PSS. Patients with lower social support were more likely to live alone (p < .
001), to be a non-Caucasian minority (p = .04), and to have more depressive symptoms (p =
0.2). Medication adherence rate was similar between higher and lower PSS groups. No age
or gender differences between higher and lower PSS groups were found.
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Medication Adherence and Cardiac Event-free Survival
During the follow-up period, 5 (2%) patients died due to cardiac reasons and 48 (21%) were
hospitalized due to HF or other cardiovascular-related diagnoses. There were no differences
in cardiac mortality between medication nonadherent and adherent patients (1% vs. 2%, p =.
6). Cardiac hospitalizations were significantly greater in medication nonadherent patients
compared to adherent patients (30% vs. 15%, p = .01). Kaplan-Meier analysis demonstrated
that the composite endpoint of cardiac event-free survival was significantly shorter in
nonadherent patients than in adherent patients (744 days vs. 930 days, p = .006). In a simple
Cox proportional hazards model (without adjusting for covariates), patients who were
medication nonadherent had 2.09 times the risk of experiencing a cardiac event than patients
who were adherent (Table 4). While the effect size of the group comparison for the Cox
proportional hazards model is not directly estimable, the observed hazard ratio associated
with the corresponding log-rank test was 1.88 (Elashof, 1995-2005; Schoenfeld, 1983). For
the Cox proportional hazards model, the observed hazard ratio for the same group effect
increased to 2.09, consistent with the expected increased power of this regression to detect a
significant group difference relative to the log-rank test (Elashof, 1995-2005; Schoenfeld,
1983).
Perceived Social Support and Cardiac Event-free Survival
There were no differences in cardiac mortality between patients with lower PSS and higher
PSS (3% vs. 2%, p = .5). Cardiac hospitalizations were significantly greater in patients with
lower PSS compared to patients with higher PSS (25% vs. 17%, p = .03). In Kaplan-Meier
analysis, the composite endpoint of cardiac event-free survival was significantly shorter in
patients with lower PSS patients than in those with higher PSS (731 days vs. 947 days, p = .
02). In a simple Cox regression model, patients who had lower PSS had 1.89 times the risk
of experiencing a cardiac event than those patients who had higher PSS (Table 4). The
observed hazard ratio for the log-rank group comparison was 1.75; this increased to a hazard
ratio of 1.89 for the group comparison within the Cox regression model.
Perceived Social Support, Medication Adherence, and Cardiac Event-free Survival—
Mediation Model
In a series of regression models and Cox-survival analyses with medication adherence and
perceived social support analyzed as continuous variables, medication adherence mediated
the relationship between perceived social support and cardiac event-free survival based on
the following sequence of regression analyses. First, in Path A (Figure 1), perceived social
support independently predicted medication adherence (p = .008). Second, in Path B,
medication adherence predicted cardiac event-free survival (p = .023). Third, in Path C,
perceived social support was an independent predictor of cardiac event-free survival (p = .
03). In the final Path D, perceived social support was no longer a significant predictor of
cardiac event-free survival when medication adherence was entered into the model (p = .09),
indicating medication adherence mediated the relationship between perceived social support
and better event-free survival.
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Perceived Social Support, Medication Adherence, and Cardiac Event-free Survival—
prediction of cardiac event-free survival from the combination of medication adherence
and perceived social support
First, we entered the interaction term of medication adherence and perceived social support
analyzed as continuous variables into a Cox proportional hazards regression model. The
interaction term of medication adherence and perceived social support significantly
predicted cardiac event-free survival before and after adjusting for study group, age, gender,
ethnicity, living status, NYHA class, and presence of depressive symptoms (p = .002 and .
040, respectively).
Second, we classified patients into one of the four groups stratified by medication adherence
and perceived social support. Of the total sample, 70 (32%) patients were classified as
medication adherent with higher perceived social support, 58 (27%) were medication
adherent with lower perceived social support, 40 (18%) were medication nonadherent with
higher perceived social support, and 50 (23%) were medication nonadherent with lower
perceived social support. These 4 groups were relatively equal in size. Using Kaplan-Meier
survival curves and log-rank tests, patients who were nonadherent and had lower levels of
PSS experienced the shortest cardiac event-free survival among all groups (p = .003). Based
on Cox regression modeling (Figure 2 & Table 5), patients with medication nonadherence
and lower level of PSS had a 3.46 times higher risk of adverse events than those with
medication adherence and higher levels of PSS (p = .001). When adding study group, age,
gender, ethnicity, living status, NYHA functional class, and presence of depressive
symptoms to the model, patients who were nonadherent and had lower levels of PSS had a
2.5 times higher risk of cardiac events than patients who were adherent and had higher level
of PSS (Table 5). The interaction term of medication adherence and perceived social support
predicted cardiac event-free survival and the lowest survival rate and highest hazard ratio
were found in patients who were nonadherent and had lower levels of PSS (Figure 2 &
Table 5), which demonstrated that medication adherence and higher PSS in combination,
predicted better cardiac-event survival.
In addition, minority status and greater depressive symptoms also predicted lower cardiac
event-free survival (p < .05). The observed hazard ratios ranged from 1.72 to 3.46 in the
unadjusted model and between 1.25 and 2.47 in the Cox regression model with covariates
included. For both models, the hazard ratio for the comparison of the low adherence/lower
PSS group to others was significant, while other group comparisons were not.
DISCUSSION
This is the first study to explore the prediction of cardiac event-free survival from the
combination of medication adherence and perceived social support in patients with HF. We
found that medication adherence and perceived social support both independently predicted
cardiac event-free survival in patients with HF when medication adherence and perceived
social support were analyzed as either dichotomized or continuous variables. Consistent
with prior studies, HF patients who were adherent to prescribed medications had a lower risk
of cardiac events than those who were nonadherent (Wu, et al., 2008; Wu, et al., 2009).
Likewise, HF patients who reported lower perceived social support had a higher risk of
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cardiac events than those who reported higher perceived social support (Burg, et al., 2005;
Happ, et al., 1997; Krumholz, et al., 1998; Luttik, et al., 2005; Tsuchihashi-Makaya, et al.,
2009; Vinson, et al., 1990). Our study extends these findings by demonstrating that
medication adherence mediates the relationship between perceived social support and
outcomes in patients with HF. This finding underscores the importance of bolstering
perceived social support in patients with HF, leading to better medication adherence, which
positively affects outcomes.
The most striking finding from this study was that medication adherence and perceived
social support, not only had independent effects, but in combination, medication adherence
and PSS also predicted cardiac event-free survival in patients with HF. In this study, the
interaction term of medication adherence and perceived social support predicted cardiac
event-free survival. When medication adherence and PSS were dichotomized and used in the
Cox regression model, the risk of experiencing a cardiac event for patients with medication
nonadherence and lower PSS was 3.5 times compared to those who were medication
adherent with higher PSS; while the risk of experiencing a cardiac event for patients with
only one risk factor was about 2 times that of those with neither risk factor.
Perceived social support has previously been identified as a predictor of hospitalization and
death in many studies (Burg, et al., 2005; Chin & Goldman, 1997a; Happ, et al., 1997;
Krumholz, et al., 1998; Lofvenmark, et al., 2009; Luttik, et al., 2005; Schwarz & Elman,
2003; Tsuchihashi-Makaya, et al., 2009; Vinson, et al., 1990; Wright, et al., 2003). Schwarz
et al. (2003) found that caregiver informal social support significantly decreased the risk of
patient hospitalization and Chin and Goldman (1997a) found that HF patients who were
single were twice as likely to be readmitted to the hospital or to die , even after adjusting for
demographic and clinical factors (e.g., gender, history of diabetics, comorbidity burden,
admission systolic blood pressure, admission serum sodium level, serum creatinine, and ST-
T-wave changes on the initial electrocardiogram) (Chin & Goldman, 1997a). Krumholz et
al. (1998) found that the absence of emotional support was associated with 3 times the risk
over 1-year of any fatal or nonfatal cardiovascular events and Wright et al. (2003) linked the
presence of social problems to a longer length of hospital stay in HF patients. Patients who
reported loneliness also had more days hospitalized (p = .044) and more readmissions to the
hospital (p = .027) (Lofvenmark, et al., 2009). Thus, there is evidence that perceived social
support influences outcomes. However, the mechanisms that produce better outcomes are
unclear.
Prior investigators suggested that better outcomes of those with higher levels of social
support might be associated with better medication adherence (DiMatteo, 2004; Edwards,
2006; Johnson, Jacobson, Gazmararian, & Blake, 2010; Molloy, Perkins-Porras,
Bhattacharyya, Strike, & Steptoe, 2008; Sayers, et al., 2008; Simoni, Frick, & Huang, 2006;
Voils, Steffens, Flint, & Bosworth, 2005). In our study, when medication adherence and
perceived social support were analyzed as continuous variables, higher perceived social
support predicted better medication adherence. Of the six prior studies in which self-report
measures of adherence were used, all reported a relationship between medication adherence
and social support (Edwards, 2006; Johnson, et al., 2010; Molloy, et al., 2008; Sayers, et al.,
2008; Simoni, et al., 2006; Voils, et al., 2005). Sayers et al. found that emotional support
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was associated with better self-reported medication adherence (p = .05) (Sayers, et al.,
2008). In DiMatteo's meta-analysis (2004), medication nonadherence was 2 times higher
among patients who did not receive practical support, 1.35 times higher among those who
did not receive emotional support, and 1.74 times higher among patients reporting lower
levels of family cohesion. In five other studies, greater social support was associated with
better medication adherence (Edwards, 2006; Johnson, et al., 2010; Molloy, et al., 2008;
Simoni, et al., 2006; Voils, et al., 2005). Therefore, social support is important for patients to
achieve better medication adherence and lead to better outcomes.
In this study, a majority of patients with higher perceived social support were adherent to
medication prescription, and most patients with lower perceived social support were
medication nonadherent. However, it is unclear why some patients with HF who reported
higher social support were nonadherent, and why some patients with lower perceived social
support were adherent. Investigators have suggested that medication adherence is largely
facilitated by practical support (DiMatteo, 2004; Molloy, et al., 2008; Wu, Moser, Lennie, et
al., 2008). In DiMatteo's meta-analysis (2004), practical support bore the highest correlation
with medication adherence. From our previous qualitative study (Wu, Moser, Lennie, et al.,
2008), patients reported that their spouse or other caregiver contributed a great deal to
increased medication adherence through practical support by sorting their complicated
prescribed medicines and directly supervising medication administration. Because most HF
patients have physical limitations, practical support is needed to ensure that patients attend
their health care appointments to keep prescriptions current, refill the prescription, and
adhere to their medication regimen (DiMatteo, 2004; Riegel, et al., 2009; Sayers, et al.,
2008; Wu, Moser, Lennie, et al., 2008). In our study, 58 out of the 218 patients (27%) who
had lower PSS were medication adherent. And 40 patients (18%) who had higher PSS were
medication nonadherent. One possible explanation is that our measure of perceived social
support did not fully capture practical, emotional, or other important components of social
support that may promote adherence. Therefore, it is possible that patients who reported
lower perceived social support had other forms of support that allowed them to be adherent.
Moreover, medication adherence is a complex phenomenon. There are many factors related
to poor medication adherence, including lower financial status which would preclude the
purchase of medications and influence adherence behavior (Wu, Moser, Chung, & Lennie,
2008). Thus, it is possible that patients who reported higher perceived social support had
other factors that reduced their ability to be adherent to medication prescriptions.
We only identified one study in which both social support and medication adherence
predicted hospitalization in patients with HF (Vinson, et al., 1990). Vinson et al. (1990)
found that poorer social support and medication nonadherence were independent predictors
of preventable readmissions. However, the relationships among medication adherence,
social support and outcomes were not examined and the ability of these variables to predict
cardiac event-free survival from medication adherence and social support in combination
was not examined either. Our study advances our understanding of this relationship by
demonstrating that: 1) medication adherence was a mediator of the relationship between
perceived social support and cardiac event-free survival; 2) better medication adherence and
higher perceived social support in combination, predicted better cardiac event-free survival
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in patients with HF before and after controlling for age, gender, ethnicity, living
arrangement, and depressive symptoms.
When we compared sociodemographic, clinical, and psychological variables between
medication adherent and nonadherent and between higher PSS and lower PSS groups, living
arrangements (lived with another person or not), ethnicity, and the degree of depressive
symptoms were different between groups. Patients in the lower PSS group were less likely
to live with others, were more likely to be in a minority ethnicity, and had more depressive
symptoms than those in the higher PSS group. However, when we adjusted for ethnicity,
living status, and depressive symptoms in the Cox regression model, patients with
medication nonadherence and lower perceived social support still had the highest risk of
experiencing a cardiac event.
LIMITATIONS
First, there are many components of social support, such as practical and emotional social
support, and family cohesiveness and conflict (DiMatteo, 2004) that we did not measure.
These components of social support may influence medication adherence and outcomes
differently. Further research is needed to examine these components of social support, and
their influence on medication adherence and outcomes in patients with HF.
Second, medication adherence was measured for different durations in the two studies. The
difference in duration may have a potential influence on the recorded adherence level.
Therefore, we compared demographic and clinical variables, medication adherence and
perceived social support between the two samples to determine whether the two were
comparable. We also controlled for study group in the final regression model to account for
potential differences between the two studies.
Third, medication adherence measured by the MEMS may be inflated when patients know
their medication-taking behaviors were monitored (i.e., Hawthorne effect). However, the
MEMS is an objective measure of adherence and has been used widely to assess medication
adherence in the research settings (Cramer, 1995). In this study, there was a strong
relationship between adherence and outcomes, suggesting adherence was accurately
reflected by the MEMS.
CONCLUSION
Better medication adherence and higher perceived social support independently, and in
combination, predicted better cardiac event-free survival in patients with HF. These findings
highlight the importance of medication adherence and patient social support network on
patient outcomes. Interventions to improve clinical outcomes should address both
medication adherence and social support.
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Cardiac event-free survival for patients who were stratified by medication adherence and
perceived social support.
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Table 1
Sample characteristics and comparison of patient characteristics* from study 1 (adherence was measured for 3
months) and study 2 (adherence was measured for 1 month)
Characteristics Overall (N = 218) Study 1 (n = 136) Study 2 (n = 82) p
Age, years 60 ±12 61 ± 11 60 ± 12 .54
Female, % 77 (35) 41 (30) 35 (43) .08
Live with others, % 160 (73) 95 (70) 65 (79) .16
Ethnicity: minority, % 32 (15) 14 (10) 18 (22) .03
LVEF, % 36 ±14.3 35 ± 14.1 38 ± 14.1 .10
NYHA III/IV, % 123 (56) 82 (60) 41 (50) .04
Hypertension, % 168 (79) 104 (79) 64 (78) .86
Diabetes, % 96 (44) 64 (48) 32 (39) .26
Body Mass Index, kg/m2 32.2 ±7.6 31.8 ± 6.6 32.8 ± 8.8 .40
Taking ACEI, % 153 (71) 97 (71) 56 (69) .76
Taking Beta-blocker, % 200 (91) 121 (89) 79 (95) .14
Medication adherent 129 (59) 76 (56) 53 (64) .26
High perceived social support 110 (51) 70 (52) 40 (49) .14
Data are presented as means ± SD, or N (%), interval level data compared by independent t-test, categorical by Chi-square; ACEI =Angiotensin-
converting-enzyme inhibitor; LVEF = left ventricular ejection fraction; NYHA = New York Heart Association
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Table 2
Comparison of characteristics among four groups stratified by medication adherence and perceived social
support
Medication adherent Medication nonadherent p value Post hoc by
LSD test
Higher PSS (n =
70)
Lower PSS (n =
58)
Higher PSS (n =
40)
Lower PSS (n =
50)
Group A B C D
Age, years 62 ± 12 60 ± 11 61 ± 15 58 ± 9 .41 -
Female, % 20 (29) 22 (38) 17 (43) 17 (35) .48 -
Live with others, % 61 (87) 34 (59) 33 (83) 32 (65) .001 A, C > B, D
Ethnicity: minority, % 5 (7) 11 (19) 6 (15) 10 (20) .15 -
LVEF, % 36.6 ± 14.6 34.5 ± 14.8 39.2 ± 14.8 33.6 ± 12.3 .26 -
NYHA III/IV, % 30 (43) 36 (62) 27 (68) 30 (60) .12 -
Hypertension, % 48 (69) 46 (82) 34 (87) 39 (83) .08 -
Diabetes, % 24 (35) 28 (49) 23 (58) 20 (41) .11 -
Body Mass Index, kg/m2 30.9 ± 7.4 33.0 ± 7.8 33.4 ± 8.0 32.0 ± 6.8 .29 -
Taking ACEI, % 57 (83) 39 (67) 26 (65) 31 (65) .07 -
Taking Beta-blocker, % 66 (94) 52 (90) 33 (83) 47 (96) .10 -
Depressive symptom score 4.6 ± 4.7 6.6 ± 5.5 6.9 ± 5.9 7.8 ± 5.8 .01 A < B, C, D
Functional status 16.4 ± 12.6 12.1 ± 12.3 12.4 ± 9.5 14.1 ± 15.3 .22 -
Data are presented as means ± SD, or N (%), interval level data compared by Analysis of Variance (ANOVA with the Least Significant Difference
[LSD] post hoc tests), categorical by Chi-square; NYHA = New York Heart Association; LVEF = left ventricular ejection fraction; ACEI
=Angiotensin-converting-enzyme inhibitor.
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Table 3








p Higher PSS (n =
110)
Lower PSS (n =
108)
p
Age, years 61 ±11 59 ±12 .32 61 ±13 59 ±11 .10
Female, % 42 (32.8) 35 (38.9) .39 37 (33.6) 40 (37) .67
Live with others, % 95 (74.2) 66 (72.3) .88 94 (85.5) 67 (62) < .001
Ethnicity: minority, % 16 (12.5) 17 (18.9) .25 11 (10) 22 (20.4) .04
LVEF, % 35.7 ±14.7 36.4 ±13.7 .74 37.5 ±14.6 34.3 ±13.8 .10
NYHA III/IV, % 66 (51.6) 57 (63.3) .16 57 (51.8) 66 (61.1) .23
Hypertension, % 94 (74.6) 74 (85.1) .09 82 (75.2) 86 (82.7) .24
Diabetes, % 52 (41.3) 44 (48.9) .27 47 (43.1) 49 (45.8) .78
Body Mass Index, kg/m2 31.8 ±7.6 32.8 ±7.5 .37 31.8 ±7.7 32.6 ±7.4 .44
Taking ACEI, % 96 (75.6) 58 (64.4) .10 83 (76.1) 71 (65.7) .10
Taking Beta-blocker, % 118 (92.2) 81 (90.0) .63 99 (90.0) 100 (92.6) .63
Medication Adherence, % 95.9 ±3.7 64.3 ±21.9 < .001 84.6 ±20.3 81.2 ±21.8 .23
Perceived Social Support score 68.6 ±18.8 64.5 ±20.2 .13 81.5 ±10.8 52.1 ±14.5 < .001
Depressive symptom score 5.5 ±5.2 7.4 ±5.8 .01 5.3 ±5.2 7.2 ±5.7 .02
Functional status score 14.5 ±12.6 13.4 ±13 .56 15.0 ±11.7 13.1 ±13.7 .29
Data are presented as means ± SD, or N (%), interval level data compared by independent t-test, categorical by Chi-square; ACEI =Angiotensin-
converting-enzyme inhibitor; LVEF = left ventricular ejection fraction; NYHA = New York Heart Association


























: Medication adherence alone and perceived social support alone on cardiac event-free
survival (N = 218)
Variables Hazard Ratio 95% CI p
Medication adherence
**
Medication adherent 1.0 - -
Medication non-adherent 2.09 1.257 - 3.478 .01
Perceived social support
§
    Higher perceived social support 1.0 - -
    Lower perceived social support 1.89 1.136 - 3.152 .01
CI: confidence interval
*
These models are simple Cox proportional hazards regression models without inclusion of covariates.
**
Chi-square = 6.202; p = .013
§
Chi-square = 8.430; p = .004
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Table 5
Cox regression modeling: medication adherence, perceived social support and cardiac event-free survival (N =
218)
Variables Hazard Ratio 95% CI p
Simple Cox Regression: without adjustment
*
Medication adherent and higher PSS 1.0 - -
Medication adherent and lower PSS 1.718 0.803 - 3.676 .16
Medication nonadherent and higher PSS 1.937 0.855 - 4.392 .11
Medication nonadherent and lower PSS 3.458 1.710 - 6.996 .001
Cox Regression: adjusting for covariates
**
Step 1
    Study_group .836 0.484-1.444 .52
    Age .996 0.974 – 1.018 .73
    Gender .953 0.548 – 1.658 .86
    Ethnicity: minority 2.197 1.150 – 4.195 .02
    Did not live with others 1.345 0.770 – 2.350 .30
Step 2
    NYHA functional class 1.275 0.820-1.982 .28
    Depressive symptoms 1.052 1.003 - 1.104 .04
Step 3
    Medication adherent and higher PSS 1.0 - -
    Medication adherent and lower PSS 1.246 0.549 - 2.831 .60
    Medication nonadherent and higher PSS 1.685 0.731 – 3.881 .22
    Medication nonadherent and lower PSS 2.465 1.155 - 5.263 .02
CI: confidence interval, PSS = perceived social support, NYHA = New York Heart Association
*
Chi-square = 13.8, p = .003
**
Chi-square = 24.5, p = .006
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